No. of unnecessary antibiotic prescriptions
No. of unnecessary antibiotic prescriptions
The COVID-19 Physician Dilemma
To escalate or not to escalate level of care?
Some infections resolve quickly, while others lead to severe immune dysregulation, respiratory failure and death. Distinguishing between the two is challenging.
Now CE Marked!
Read the full press release HERE!
Covid-19: A global snapshot
COVID-19: A global snapshot
1 in 5
patients experience life threatening disease
1
*Numbers as of May 2021
8%
Re-admission
2
~20%
Potential over admission
3
4
$35K
Average cost per non-ICU patient
Conventional tests are important, but insufficient
to aid in effective patient management:
Conventional tests are important, but insufficient
to aid in effective patient management:
Conventional tests are important,
but insufficient to aid in effective
patient management:
Inaccurate risk stratification
Fail to alert prior to organ damage
Uncertainty regarding results interpretation
Prolonged turnaround time
Unable to capture
disease complexity
Three Biomarkers + Machine Learning = MeMed COVID-19 Severity
TM
MeMed COVID-19 Severity builds on an extensive body of evidence supporting the role of viral-induced TRAIL and IP-10 and inflammatory CRP proteins in severe SARS-CoV-2 infection.
5-7
5
From a small serum sample, MeMed COVID-19 Severity computationally integrates the levels of these three host immune proteins into a simple score indicating the likelihood of patient deterioration.
![shutterstock_740523562 white [Converted]_2_.png](https://static.wixstatic.com/media/6a0f21_6949f176cadf444ca55ed16c382f0deb~mv2.png/v1/fill/w_395,h_344,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/6a0f21_6949f176cadf444ca55ed16c382f0deb~mv2.png)
MeMed COVID-19 Severity -
Predictive & Actionable
3
• Early indication of deterioration
• Predictive of further disease progression vs. recovery
• Ease of use: single serum sample per test
• 15 minutes from sample to result
• Easy to interpret results
Actionable
Predictive
MeMed
COVID-19 Severity
Performance
TM
*Validation study results, data not published
MeMed COVID-19 Severity signature compares favorably with other biomarkers
3
Comparison of area under ROC curve (AUC)
*IMV: Intubation with mechanical ventilation
MeMed Key runs
the MeMed COVID-19 Severity test in just 15 minutes, where and when it actually matters.
®
™
MeMed Key is a cutting edge, compact immunoassay platform that makes it possible to conduct highly sensitive, multiplexed protein measurements that previously could only be done on expensive central lab equipment.
MeMed BV, MeMed Key & MeMed COVID-19 Severity are CE Marked.
MeMed COVID-19 Severity is not cleared by the FDA for any indication.
MeMed COVID-19 Severity is not currently available for sale in the US.
-
Wu, Z. & McGoogan, J. M. "Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention." JAMA 323, 1239 (2020).
-
Kilaru, Austin S., et al. "Return hospital admissions among 1419 Covid‐19 patients discharged from five US emergency departments." Academic Emergency Medicine 27.10 (2020): 1039-1042.
-
Samuel Mastboim, Niv S., et al. "An immune-protein signature combining TRAIL, IP-10, and CRP for accurate prediction of severe COVID-19 outcome." MedRxiv (2021).
-
Ivanisenko, Nikita V., et al. "The role of death domain proteins in host response upon SARS-CoV-2 infection: modulation of programmed cell death and translational applications." Cell death discovery 6.1 (2020): 1-10.
-
Osuchowski, Marcin F., et al. "The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity." The Lancet Respiratory Medicine (2021).
-
Guan, Wei-jie, et al. "Clinical characteristics of coronavirus disease 2019 in China." New England journal of medicine 382.18 (2020): 1708-1720.
Contact us for more information about our COVID-19 Severity product
